Search research articles
Contact Us
Filters
Showing results (31-40 of 77) with videos related to
Page
of 8
Sort By:
The Journal of Antimicrobial Chemotherapy
|
December 14, 2018
Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance
Anna Maria Geretti, Ellen White, Chloe Orkin, et al.
Journal of Virus Eradication
|
November 23, 2019
Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV
Oliver T Stirrup, Caroline A Sabin, Andrew N Phillips, et al.
AIDS (London, England)
|
May 11, 2002
Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy
Alexander J Frater, David T Dunn, Alison J Beardall, et al.
Journal of the International AIDS Society
|
May 22, 2021
Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial
David V Glidden, Moupali Das, David T Dunn, et al.
AIDS (London, England)
|
October 26, 2013
The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults
Nicola E Mackie, David T Dunn, David Dolling, et al.
Antiviral Therapy
|
November 3, 2010
HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom
Daniella N Chilton, Hannah Castro, Sam Lattimore, et al.
Virus Evolution
|
July 15, 2025
Evidence for circulation of high-virulence HIV-1 subtype B variants in the United Kingdom
Vinicius B Franceschi, Kieran O Drake, David F Bibby, et al.
The International Journal on Drug Policy
|
November 19, 2019
Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants
Charlotte O'Halloran, Brian Rice, Ellen White, et al.
AIDS Research and Therapy
|
April 18, 2018
Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data
Oliver T Stirrup, David T Dunn, Anna Tostevin, et al.
BMJ (Clinical Research Ed.)
|
June 17, 2024
Exploring different objectives in non-inferiority trials
Conor D Tweed, Matteo Quartagno, Michelle N Clements, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 77) with videos related to
Sort By:
Page
of 8
The Journal of Antimicrobial Chemotherapy
|
December 14, 2018
Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance
Anna Maria Geretti, Ellen White, Chloe Orkin, et al.
Journal of Virus Eradication
|
November 23, 2019
Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV
Oliver T Stirrup, Caroline A Sabin, Andrew N Phillips, et al.
AIDS (London, England)
|
May 11, 2002
Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy
Alexander J Frater, David T Dunn, Alison J Beardall, et al.
Journal of the International AIDS Society
|
May 22, 2021
Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial
David V Glidden, Moupali Das, David T Dunn, et al.
AIDS (London, England)
|
October 26, 2013
The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults
Nicola E Mackie, David T Dunn, David Dolling, et al.
Antiviral Therapy
|
November 3, 2010
HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom
Daniella N Chilton, Hannah Castro, Sam Lattimore, et al.
Virus Evolution
|
July 15, 2025
Evidence for circulation of high-virulence HIV-1 subtype B variants in the United Kingdom
Vinicius B Franceschi, Kieran O Drake, David F Bibby, et al.
The International Journal on Drug Policy
|
November 19, 2019
Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants
Charlotte O'Halloran, Brian Rice, Ellen White, et al.
AIDS Research and Therapy
|
April 18, 2018
Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data
Oliver T Stirrup, David T Dunn, Anna Tostevin, et al.
BMJ (Clinical Research Ed.)
|
June 17, 2024
Exploring different objectives in non-inferiority trials
Conor D Tweed, Matteo Quartagno, Michelle N Clements, et al.
Page
of 8